tinostamustine

Small moleculeexperimental

Clinical trial activity

7 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2016 (NCT02576496)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

Chemistry & pharmacology

Loading structure…

SMILES

Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21
Mol. weight
415.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • edo-s101
  • edo-s101
  • tinostamustine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05432375Early Phase 1 (Phase 1)Jul 1, 2022Mundipharma
NCT03903458Phase 1Mar 7, 2019Cantonal Hospital of St. Gallen
NCT04279938Phase 1Sep 30, 2018Merck, Mundipharma, Royal Marsden Hospital NHS Trust
NCT03687125Phase 1/Phase 2 (Phase 2)Sep 19, 2018Mundipharma
NCT03452930Phase 1Aug 13, 2018Mundipharma, University of Texas at Houston
NCT03345485Phase 1/Phase 2 (Phase 2)Oct 6, 2017Mundipharma, Stanford University
NCT02576496Phase 1Mar 1, 2016Columbia University, Mundipharma
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MundipharmaFor profit6422016
Cantonal Hospital of St. GallenAcademic/Hospital1112019
Columbia UniversityAcademic/Hospital1012016
MerckFor profit1012018
Royal Marsden Hospital NHS TrustAcademic/Hospital1112018
Stanford UniversityAcademic/Hospital1012017
University of Texas at HoustonAcademic/Hospital1112018
7 organizations
Page 1 / 1